CIRM
Industry & Stem Cells in California: Fostering R&D

July 25, 2006

Human Embryonic Stem Cells

Self-Renewing Source for the Scalable Manufacturing of Replacement Cells for Every Tissue in the Body



Blastocyst



Human Embryonic Stem Cells



Hepatocytes



Chondrocytes



Osteoblasts

Arthritis

Drug Discovery



Hematopoietic Cells



Islets

Osteoporosis And Bone Fractures



Cardiomyocytes

Neural Cells



Bone Marrow Transplant



Diabetes



Heart Failure



Parkinson's Disease



Spinal Cord Injury

geron

Human Embryonic Stem Cells

Milestones Achieved on the Path to Clinical Development of GRNOPC1, Our hESC-Derived Glial Progenitor Cells for Spinal Cord Injury



Spinal Cord Injury Phase 1-2 Study Design

- Unblinded, Randomized Controlled Trial
  - Escalating Doses Up to $2x10^7$ Cells
- Transplant 7-14 Days Post Injury
- Subacute, Functionally Complete T3-T12 Lesions
- 3 Months Evaluation / 9 Months Follow-Up
- Temporary Immunosuppression with Cyclosporine
- Primary Endpoint: Safety
  - Neurological
  - Overall
- Secondary Endpoints: Efficacy
  - ASIA Grade and Score
  - Independence Measurements
  - Bowel and Bladder Function



geron


geron